Avexima and FC Grand Capital are considering medicines development on Russky Island
Avexima, together with national pharmaceutical distributor FC Grand Capital, are considering a project to set up innovative laboratories on Russky Island to reproduce and develop advanced medicines.
Avexima, together with national pharmaceutical distributor FC Grand Capital, are considering a project to set up innovative laboratories on Russky Island to reproduce and develop advanced medicines.
Representatives of Avexima assessed the feasibility of the large-scale project during a working visit to Primorye on 23-24 March 2022.
Avexima's expertise in implementing high-tech pharmaceutical development and manufacturing projects with the financial participation of the national pharmaceutical distributor, FC Grand Capital, will not only significantly speed up the establishment of laboratories and market launch of innovative developments, but also organise the distribution and prompt delivery of developed and reproduced medicines to each subject of the Russian Federation in the shortest possible time.
Over two days, together with the Russian Science and Technology Development Foundation, the delegation visited the science and education units of FEFU, familiarised themselves with the preliminary layout of the science and education clusters, toured the pilot site of the innovative science and education centre, and visited the production facilities of one of its promising residents, the Arnika Group.
Yelena Kharisova, head of the Russky Innovative Center of Science and Technology Development Fund, offered several options for companies to participate in the project at the end of the workshop.
"The reproduction and development of modern medicines in Russia is one of the most important government tasks. We invite you to take part in a pilot project where there is an opportunity to test the model of interaction between the company and the university, in particular as regards training. We would also be glad to see you as a resident of the Biomedicine scientific and educational cluster, which fully reflects the specific nature of your activities," said Yelena Kharisova.
Igor Onokhov, head of the Development and Project Implementation Department, expressed interest in participating in the project.
"At the moment, Avexima already has a successful R&D centre in Skolkovo. It is important for us that the projects do not duplicate, but complement each other. That is why, in the first place, we have to decide on the concept of where the innovation labs should be located," he explained.
During the visit, the delegation was able to learn about the latest medical and pharmaceutical developments in the Far East. Vadim Kumeiko, deputy director for development at FEFU's Institute of Life Sciences and Biomedicine, presented his developments.
In addition, representatives of Avexima toured the production facilities of the Arnika Group. During the tour, company representatives discussed projects by scientists from the Far East that could be used to develop pharmacology and new medicines in Russia, as well as other promising joint projects, including at the Innovative Center of Science and Technology.
Avexima JSC is one of Russia's largest producers of active pharmaceutical ingredients and pharmaceuticals. The company's chemical and pharmaceutical plants are located in Moscow, Kemerovo and Sverdlovsk Regions. The product range includes medicinal products from various pharmacotherapeutic groups with a total production capacity of more than 1.5 billion units of finished products per year.
On the margins of the Eastern Economic Forum in 2021, the Russky Innovative Center of Science and Technology Development Fund and Avexima signed an agreement of intent on long-term cooperation.
"Our goal is to create an R&D complex in the pharmaceutical industry. These are modern pilot sites for the production of medicines, nutritional supplements and medical devices in accordance with the GMP standard on the basis of the centre. A pilot project to introduce products with high export potential - antiviral and immune drugs - to Asia-Pacific markets as a participant in the Russky Innovative Center of Science and Technology project is planned to be launched in the very near future," said Yelena Tkachenko, General Director of the pharmaceutical company Avexima JSC that time.